



Toxicology Assessment Report
For
Skin Sensitization
C1=NC=NC(Cl)=C1
4,6-dichloropyrimidine

REACH*Across*[™] 3.1.4 estimates a 96% probability of Skin Sensitization hazard for C1C1=NC=NC(CI)=C1.

The below resources will aid in completing your IUCLID submission:

1. [ECHA - How to use and report \(Q\)SARs](#)
2. [REACH*Across*[™] Documentation](http://ulreachacross.com) <http://ulreachacross.com>
3. [REACH*Across*[™] QMRF](http://ulreachacross.com/Documents/QMRF.xml) <http://ulreachacross.com/Documents/QMRF.xml>
4. [REACH*Across*[™] QPRF](http://ulreachacross.com/Documents/QPRF.txt) <http://ulreachacross.com/Documents/QPRF.txt>

The below information is supplied to aid in completing a(n) Skin Sensitization submission in IUCLID:

ADMINISTRATIVE DATA

Type of information:

(Q)SAR

Reliability:

2 (reliable with restrictions)

Rationale for reliability:

Results derived from a valid (Q)SAR model and falling into its applicability domain, with adequate and reliable documentation / justification.

Justification for type of information

Software:

<http://ulreachacross.com/>

Model (incl. version number):

REACH*Across*[™] v3.1.4

SMILES or other identifiers used as input for the model:

C1C1=NC=NC(CI)=C1

Scientific validity of the (Q)SAR model:

- Defined endpoint: Skin Sensitization
- Unambiguous algorithm: REACH*Across*[™] provides an unambiguous algorithm definition at <http://ulreachacross.com/Documents/reachacross-1.0.0-wp.pdf>
- Defined domain of applicability: REACH*Across*[™] 3.1.4 defines a probabilistic domain of applicability. Substances predicted with sufficiently high or low probability are included in the domain of applicability.
- Appropriate measures of goodness-of-fit and robustness and predictivity: REACH*Across*[™] 3.1.4 uses leave one out cross validation on the ECHA C&L database. These results are reported at <http://ulreachacross.com/Documents/reachacross-1.0.0-wp.pdf>
- Mechanistic interpretation: N/A

Applicability domain:

- Descriptor domain: Pubchem2D Fingerprints and Similarity Network Features
- Structural and mechanistic domains: Defined by model predictions

- Similarity with analogues in the training set: NA
- Other considerations (as appropriate): NA

Adequacy of the result:

REACH*Across*[™] 3.1.4 provides a cross validated prediction of human health hazards. This algorithm is built from billions of chemical similarity comparisons in the UL integrated database and tested on ECHA C&L data. A robust summary is given at <http://ulreachacross.com/Documents/reachacross-1.0.0-wp.pdf>

Attached Justification:

- Attach the given QMRF (available at <http://ulreachacross.com/Documents/QMRF.xml>)
- Attach the given QPRF (available at <http://ulreachacross.com/Documents/QPRF.txt>)

DATA SOURCE

Reference

Title:

REACH*Across*-3.1.4 Platform

Reference Type:

Other: other software

Author:

UL Verification Services, Inc.

Year:

2017

Bibliographic source:

<http://ulreachacross.com/>


MATERIALS AND METHODS**Principles of method if other than guideline:**

REACH*Across*[™] v3.1.4 is a hybrid QSAR and read across model that uses chemical similarities paired with supervised learning to make probabilistic estimates on hazard. Documentation including validation reports and methods information are available at <http://ulreachacross.com/Documents/reachacross-1.0.0-wp.pdf>. The platform is available at <http://ulreachacross.com/>

RESULTS AND DISCUSSION

Applicant's summary and conclusion

Target:



4,6-dichloropyrimidine

ClC1=NC=NC(Cl)=C1

Hazard Analogues		Non-Hazard Analogues	
Structure	Name	Structure	Name
 93% Similar	2,4-dichloropyrimidine	 68% Similar	3-hydroxy-2-imino-6-pyrrolidin-1-ylpyrimidin-4-amine
 92% Similar	2,4,6-trichloropyrimidine	 65% Similar	6-chloro-7H-purin-2-amine
 84% Similar	4,6-dichloro-2-ethoxypyrimidine	 62% Similar	2,6-diamino-1H-pyrimidin-4-one
 78% Similar	pyrimidine-2-carbonitrile	 62% Similar	4,6-dimethoxypyrimidin-2-amine
 72% Similar	2-ethoxy-4,6-difluoropyrimidine	 58% Similar	4,4-dimethyl-1-[4-(4-pyrimidin-2-yl)piperazin-1-yl]butyl]piperidine-2,6-dione;hydrochloride

Interpretation of results:

Skin Sensitization Hazard

Potency:

Potency Category	Probability
H317: Skin Sens. 1	2%
H317: Skin Sens. 1b	43%
(Skin Sensitization,3)	50%

Conclusions:

REACHAcross™ v3.1.4 estimates a 96% probability that C1C1=NC=NC(Cl)=C1 is a skin sensitizer

Hazard	Probability
Skin Sensitization Hazard	96%
Not Skin Sensitization Hazard	4%

© 2017 UL LLC. All rights reserved. This document is for internal UL customer use only. You are responsible for reviewing its content prior to further distribution or publication of its contents and are solely responsible for any published or distributed report. The name, brand or marks of UL cannot be used in any packaging, advertising, promotion or marketing relating to the data in this Toxicology Assessment Report. The information provided in this Toxicology Assessment Report is correct to the best of our knowledge, information and belief at the date of its publication. UL did not test, certify or approve the chemicals described in this Toxicology Assessment Report. The information provided relates only to the specific chemicals designated and may not be valid for use in combination with any other materials or in any process. This report is not a statement of compliance. UL makes no representations or warranties regarding the completeness or accuracy of the information presented and disclaims all liability in connection with the use of this information.


ReachAcross 3.1.4 Binary Evaluation

REACH_{Across} 3.1.4 predicts chemical hazard potencies for 8 endpoints:

1. acute dermal (negative, h313, h312, h311, h310)
2. mutagenicity (negative, h340, h341)
3. acute oral (negative, h303, h302, h301, h300)
4. acute aquatic (negative, h402, h401, h400)
5. chronic aquatic (negative, h413, h412, h411)
6. skin sensitization (negative, h317 type 1, h317 type 1b)
7. skin corrosion irritation (negative, h316, h315, h314)
8. eye damage irritation (h320, h319, h318)


The below figures evaluate REACH_{Across} performance in predicting binary hazards.

1 Negative / Positive Distribution over Hazard Probability



The above plots are density plots with **blue positives** and **orange negatives**. Ideally the orange density would be on the far left and blue density on the far right.


2 Prevalence Adjusted Positive / Negative Ratio



The above plots are **adjusted ratios of negatives (orange) to positives (blue)** at each probability of hazard. Ratios are adjusted to account for prevalence. For many of these endpoints there are far more positives than negatives. To account for this difference in prevalence negatives and positives are weighted to create an equal **adjusted prevalence**.

3 Accuracy vs Coverage

In general there is a tradeoff between coverage and accuracy. In the below graphs balanced accuracy increases above 80% (top black line) for every endpoint and coverage drops to 0% for every endpoint as threshold for prediction increases.



4 Sensitivities and Specificities

The terms in the below table are defined below:

1. **negative threshold (negT)**: a probability value below which a negative call is made
2. **positive threshold (posT)**: a probability value above which a positive call is made
3. **Sensitivity (Se)**: Percent of covered hazardous compounds correctly predicted.
4. **Specificity (Sp)**: Percent of covered non-hazardous compounds correctly predicted.
5. **Balanced Accuracy (BAC)**: a measure of accuracy ($1/2$ sensitivity * $1/2$ specificity).
6. **coverage (cover)**: Percent of labeled compounds that falls above/below the pos/neg threshold.

Thresholds were selected to:

1. optimize balanced accuracy
2. optimize coverage
3. maintain equal distance between 0.5 and the negative and positive thresholds

endpoint	pos	neg	total	negT	posT	Se	Sp	BAC	cover
skin sensitization	2865	1886	4751	41%	59%	79%	63%	71%	75%
eye damage irritation	14778	944	15722	41%	59%	83%	56%	70%	79%
acute oral	10225	1932	12157	41%	59%	77%	77%	77%	82%
mutagenicity	600	2795	3395	41%	59%	75%	71%	73%	76%
skin corrosion irritation	13757	1348	15105	41%	59%	69%	71%	70%	76%
acute dermal	4322	1978	6300	41%	59%	77%	75%	76%	82%
acute aquatic	1122	921	2043	41%	59%	76%	74%	75%	77%
chronic aquatic	2552	251	2803	41%	59%	78%	66%	72%	79%

Balanced accuracies are over 70% for every endpoint. Coverage is over 70% for every endpoint. With the exception of skin corrosion/irritation sensitivities are above 70% for every endpoint.